Iconovo CEO Dr Orest Lastow will speak at Connectivity in Medical Technology organized by Management Forum in London 24-25 June. The speach is titled “The use of electronics to improve and monitor compliance”. The speach will focus on the use of electronics in ICOone and ICOres as a mean to improve adherence and compliance by offering an improved user interface. The main topics of the talk are:

  • Opportunities to improve compliance with better user interface
  • The benefits of electronics in clinical trials
  • Risks and undesired effects of compliance monitoring

The development of Iconovo’s proprietary capsule based inhaler, ICOcap has reached an important milestone. The first mold tools have been manufactured and the first injection molded devices have been delivered. The mold tools are single cavity technical tools and will be used to produce devices for mechanical verification and performance testing together with clients.

Orest Lastow is the co-author of a recently published book titled “Pulmonary Drug Delivery: Advances and Challenges”. The book addresses problems associated with inhalation formulation design, including the interaction between the active pharmaceutical ingredient(s) (APIs), excipients and devices. Orest has written chapter 16 “Future Patient Requirements on Inhalation Devices: The Balance between Patient, Commercial, Regulatory and Technical Requirements”, see table of contents. The book is available directly from Wiley and from e.g. Amazon.com.

Iconovo CEO Dr Orest Lastow has been invited to give a presentation about the Iconovo inhalation devices at the Dry Powder Inhaler Conference organized by Management Forum in London 10-11 June. The speach is titled “Iconovo Device Range” and will include the following topics.

  • Key strategies when developing a versatile and comprehensive device platform
  • How to develop novel devices that are equivalent to devices on the market
  • BE challenges on devices for generic products
  • Key features, results and lessons learned

Iconovo´s CEO Dr Orest Lastow will be moderating the New Updates in Drug Formulation and Bioavailability conference in Copenhagen 7 April. Formulation and bioavailability are critical steps in the development process of new effective drugs. Failure in clinical trials can often be explained by poor formulation and bioavailability properties of the drug. The conference is open for registration and expects to attract 100 delegates and 12 exhibitors.

Iconovo has invested in the Autodesk Simulation CFD software. Iconovo CEO Dr Orest Lastow was previously head of the AstraZeneca CFD group and has long experience from the optimization of the aerodynamics in inhalation devices. More details about the software at autodesk.com.

Iconovo has moved into new lab facilities. The new facilities will allow us to perform verification and performance testing of the devices in development. Iconovo has access to carrier based formulations and micronized spheronized formulation for testing.

Iconovo CEO Dr Orest Lastow has published a paper in Journal of Aerosol Medicine and Pulmonary Drug Delivery. The paper is titled “Orally Inhaled Drug Performance Testing for Product Development, Registration, and Quality Control” and describes different approaches to testing inhalation products during development. The paper is available at liebertpub.com.

Iconovo was a silver sponsor at DDL 25 in Edinburg, DDL Conference. DDL is the internationally most important inhalation conference held annually in Edinburg. Over 600 delegates representing all major pharmaceutical companies and generic companies. We had an exposition showing our device line-up. There was a great interest in our devices and we met many new potential customers.

Iconovo has raised 1 million USD in venture capital funding to develop inhalation devices. Lennart Holm has also increased his equity share in the company. Lennart Holm is the chairman of the board of the Swedish company BillerudKorsnäs AB and also of Nexam AB and Vigmed AB. Iconovo is based at Medicon Village in Lund and is founded, among others, by ex AstraZeneca employees. Iconovo is developing proprietary dry powder inhaler devices for licensing to pharmaceutical companies. The primary market is generic companies planning to enter the inhalation business but lacking access to devices. The devices are primary intended for asthma and COPD but also for vaccines and biomolecules. “This funding will take us to a level where we have injection molded prototypes with verified performance”, says Orest Lastow, CEO of Iconovo.